Clinical case long-term care of the patient with mCRPC

Patients with metastatic castration-resistant prostate cancer (mCRPC) have a poor prognosis, and those patients with metastases areexpected to survive ≤19 mo. As patientsʼ disease progresses, quality of life deteriorates, and until recently, few treatment options were available. Several new therapies have shown an improvement in overall survival for patients with mCRPC who have already received chemotherapy with docetaxel. The impact of these new data on daily clinical practice, treatment sequencing, and best care for individual patients is not yet fully understood. Early detection of castration resistance before the development of clinical symptoms and significant prevalence of tumor gives patients the opportunity to receive as many lines of drug therapy with a satisfactory quality of life, which, of course, leads to an increase in overall survival. Here we present clinical case long-term care of the patient with mCRPC.